Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Lexaria Bioscience Q3 EPS $(0.13) Misses $(0.10) Estimate, Sales $84.00K Miss $150.00K Estimate

Author: Benzinga Newsdesk | July 12, 2024 02:07pm

Lexaria Bioscience (NASDAQ:LEXX) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.10) by 30 percent. This is a 64.86 percent increase over losses of $(0.37) per share from the same period last year. The company reported quarterly sales of $84.00 thousand which missed the analyst consensus estimate of $150.00 thousand by 44.00 percent. This is a 8.10 percent increase over sales of $77.71 thousand the same period last year.

Posted In: LEXX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist